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RESEARCH ARTICLE Open Access
Inorganic Arsenic-induced cellular transformation is
coupled with genome wide changes in chromatin
structure, transcriptome and splicing patterns
Caitlyn Riedmann1†, Ye Ma1†, Manana Melikishvili1, Steven Grason Godfrey1, Zhou Zhang2, Kuey Chu Chen3,
Eric C Rouchka4 and Yvonne N Fondufe-Mittendorf1*
Abstract
Background: Arsenic (As) exposure is a significant worldwide environmental health concern. Low dose, chronic
arsenic exposure has been associated with a higher than normal risk of skin, lung, and bladder cancer, as well as
cardiovascular disease and diabetes. While arsenic-induced biological changes play a role in disease pathology, little
is known about the dynamic cellular changes resulting from arsenic exposure and withdrawal.
Results: In these studies, we sought to understand the molecular mechanisms behind the biological changes induced
by arsenic exposure. A comprehensive global approach was employed to determine genome-wide changes to chromatin
structure, transcriptome patterns and splicing patterns in response to chronic low dose arsenic and its subsequent
withdrawal. Our results show that cells exposed to chronic low doses of sodium arsenite have distinct temporal and co-
ordinated chromatin, gene expression, and miRNA changes consistent with differentiation and activation of multiple bio-
chemical pathways. Most of these temporal patterns in gene expression are reversed when arsenic is withdrawn.
However, some gene expression patterns remained altered, plausibly as a result of an adaptive response by cells. Addition-
ally, the correlation of changes to gene expression and chromatin structure solidify the role of chromatin structure in gene
regulatory changes due to arsenite exposure. Lastly, we show that arsenite exposure influences gene regulation both at
the initiation of transcription as well as at the level of splicing.
Conclusions: Our results show that adaptation of cells to iAs-mediated EMT is coupled to changes in chromatin structure
effecting differential transcriptional and splicing patterns of genes. These studies provide new insights into the mechanism
of iAs-mediated pathology, which includes epigenetic chromatin changes coupled with changes to the transcriptome
and splicing patterns of key genes.
Keywords: Gene expression, Genome-wide, Chromatin, Arsenic, Splicing
Background
Arsenic, a ubiquitous metalloid, is one of the most com-
mon environmental pollutants, with human exposure
occurring mainly through contaminated drinking water.
In some regions of the world, especially coal mining
regions, inorganic arsenic (iAs) levels in drinking water
can exceed those recommended by the World Health
Organization [1,2]. Long-term exposure to iAs is associ-
ated with the etiology of several diseases including
coronary heart disease, hypertension, arteriosclerosis and
multiple cancers [3-5]. Although arsenic is a recognized
human carcinogen, the mechanism(s) by which it causes
cancer remains elusive.
Arsenic is found in several different chemical forms and
oxidation states and its metabolism has an important role
in its toxicity. In mammals, the metabolism of arsenic is
catalyzed by Arsenic (+3 oxidation state) methyltransfer-
ase 1 (AS3MT 1) which catalyzes conversion of iAs to
methylated arsenicals. This process involves a sequential
reduction of iAs5+ to iAs3+ followed by oxidative methyla-
tion to monomethylarsonic acid (MMA5+) and dimethy-
larsinic acid (DMA5+). Some of the intermediates of this
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process, the trivalent intermediate arsenicals, MMA3+ and
DMA3+, have been implicated in arsenic toxicity, acting as
potent cytotoxins and enzyme inhibitors. Arsenic thus
causes oxidative stress, apoptosis and mutagenesis, all
mechanisms important for its carcinogenic potential
[reviewed in [6]. However, since arsenic does not cause
point mutations [7,8], other mechanisms have been impli-
cated in its toxicity. Accumulating evidence suggests that
aberrant gene expression due to non-genotoxic modifica-
tions may play crucial roles in arsenic-mediated carcino-
genesis [9-11]. Furthermore the lack of a prominent signal
transduction mechanism has led to the belief that arsenic
is an epigenetic carcinogen. Nonetheless, signal transduc-
tion pathways can integrate arsenic-induced signals into
specific transcriptional states, characterized by chromatin
structures that activate or repress transcription at specific
gene loci. Although a large variety of signal transduction
pathways have already been described, much less is known
about the crosstalk between signal transduction and the
consequent changes in chromatin structure that lead to
changes in gene expression.
In order to understand the mechanism of iAs toxicity
several microarray-based gene expression studies have
been conducted [3]. These studies have shown wide-
spread disruption of transcriptional activity following
iAs exposure with extensive changes in global gene ex-
pression, suggesting that diverse regulatory mechanisms
of gene expression might be affected. However, most of
these studies have analyzed gene expression changes
caused by acute phase responses and instant adaptation
of cells to iAs insult. Lacking are comprehensive studies
on low-dose, long-term iAs exposure. Such studies will
have a fundamental impact on our understanding of
arsenic-disease developmental changes. Equally important
and lacking is an understanding of whether iAs-induced
gene expression changes are reversible upon removal of
the toxic insult, and if so to what extent. Lastly, it remains
to be determined whether iAs influences mRNA splicing
patterns.
Arsenic is known to transform cells through the
epithelial-to-mesenchymal transition (EMT) [12,13]. Al-
though arsenic-regulated expression of individual genes
has been intensively studied, the biological consequences
of global chromatin, transcriptome and splicing changes
caused by this metal during EMT remain unexplored. To
increase our understanding of the underlying molecular
mechanisms of iAs-induced EMT, we investigated the con-
sequences of protracted iAs exposure and its subsequent
withdrawal on chromatin structural changes, gene expres-
sion and alternative splicing. Our findings demonstrate
that the adaptational changes due to iAs exposure involve
changes to chromatin structure, gene expression as well as
the production of specific gene isoforms. Additionally,
withdrawal of iAs results in the restoration of some, but
not all, chromatin structures and gene expression patterns.
The permanent alteration of some gene expression pat-
terns possibly could be linked with disease etiology associ-
ated with arsenic exposure. Additionally most of these
patterns were consistent in both HeLa and BEAS-2B cells,
suggesting some pathways modulated by iAs might be
universal.
Results
Exposure to low doses of sodium arsenite suppresses cell
growth and modulates cell morphology
To understand the effect of long-term iAs exposure on
cells resulting in EMT, we carried out studies in normal
lung epithelial BEAS-2B cells, bearing in mind that the
lung is a major cellular target of iAs carcinogenesis
[4,14-18]. In addition to normal BEAS-2B cells, we also
used the cervical cancer cell line, HeLa, a commonly
used model cell line to study cancer cell signaling and
EMT. We used these cells lines to assess whether the
observed iAs-mediated effects were applicable to both
normal and malignant cells. We initially investigated the
effect of sodium arsenite (iAs3+) on the proliferation of
these cells using environmentally relevant doses of ≤1 μM
[19,20]. Higher concentrations of iAs were briefly exam-
ined and as expected led to consistent cell death. Our ex-
perimental design is described in Figure 1.
Cells were cultured with and without 0.5 μM and 1 μM
iAs for 16 weeks (Figure 1), during which time we moni-
tored their morphology and growth rates (Figure 2). In
“phase 1” (36 days for BEAS-2B and 45 days for HeLa),
iAs-treated cells showed slow growth compared to time-
matched non-treated (NT) cells (Figures 2A – D). These
data are consistent with previous studies that showed in-
hibition of cell growth due to iAs exposure [12]. In “phase
II” (after 36 days for BEAS-2B and 45 days for HeLa),
changes in growth and cell morphology became apparent
as iAs-treated cells grew faster than NTcells and even sur-
passed their non-exposed counterparts (Figures 2A - D).
HeLa cells became rounder, grew on top of each other and
lost their filapodia (Figure 2A), while BEAS-2B cells be-
came more fibroblast-like (Figure 2B). These results are
comparable with reported malignant transformations by in-
organic arsenic in other cell lines [21]. We hypothesize that
these changes in cell morphology and increased growth rate
in both cell-types indicate a point of transformation of
iAs-treated cells possibly undergoing an EMT.
To confirm that indeed we are observing an EMT, we
examined whether the expression of EMT markers were
concomitantly altered. Cell lysates were probed using
antibodies against vimentin and claudin-3, known EMT
markers, in Western blot analyses. We found that
claudin-3 protein levels were downregulated by ~65% in
iAs-exposed cells. On the other hand, vimentin protein
levels were highly induced by iAs exposure (40% increase
Riedmann et al. BMC Genomics  (2015) 16:212 Page 2 of 19
compared to NT cells in both cell types). Interestingly re-
moval of arsenite resulted in a reversal of these changes in
protein levels, additionally, this effect was dose dependent
as we observed more expression of vimentin in 1 μM
compared to 0.5 μM arsenite treatment (Figure 2C and
Additional file 1: Figure S1). Henceforth, we will refer to
these cells as iAs-transformed (iAs-T) cells.
Arsenic-exposure results in an increased lifespan of cells
To determine the effect of iAs on population-doubling cap-
acity, BEAS-2B and HeLa cells were continuously cultured
in growth media containing 1 μM iAs. Exposure of the
HeLa cells to iAs did not have an effect on the cell prolifer-
ation rate as the cells doubled as fast as NTcells (Figure 2E).
We attribute this to the fact that these cells are carcino-
genic. However treated BEAS-2B had a slower population-
doubling rate and a longer in vitro lifespan compared to
NT cells (Figure 2F). These iAs-treated BEAS-2B cells grew
continuously without a detectable senescent phenotype
[13], possibly mirroring iAs transformation of these cells.
Taken together, our results support the idea that signal
transduction mechanisms elicited by low doses of iAs
exposure and subsequent induction of defense mechanisms
contribute to longevity.
Low doses of iAs does not induce DNA fragmentation
In order to determine if a chronic low dose of iAs expos-
ure results in apoptosis, we tested for genomic DNA
laddering, a well characterized marker for apoptosis [22].
DNA from the NT, 0.5 μM and 1 μM iAs-treated cells
(both BEAS-2B and HeLa cells) was purified and ana-
lyzed using agarose gel electrophoresis. We found that
chronic low doses of iAs did not induce DNA fragmenta-
tion in these cells (Additional file 2: Figure S2). While our
bulk studies do not exclude the possibility of some level of
apoptosis occurring, they suggest that other mechanisms
are likely responsible for the gene expression changes ob-
served in iAs-induced cellular transformation. One likely
mechanism for the changes in gene expression observed
in iAs-transformed cells is modulation to their epigenome.
Low doses of arsenite induce structural changes to
chromatin
Differentiating cells undergo programmed alterations in
their patterns of gene expression, which are often regulated
by structural changes in chromatin. We therefore asked if
iAs induces changes to chromatin structure during the
process of iAs-mediated cellular transformation. To this
end, we used several methods to test for chromatin struc-
tural changes - bulk nucleosome repeat length (NRL),
micrococcal (MNase) resistance and the presence of the
repressive histone H1.
For bulk NRL changes, we isolated nuclei from NT
and iAs-T cells to ensure maximal effect of arsenite
treatment. Chromatin was digested in situ with different
concentrations of MNase, and the resulting partially
Figure 1 Experimental design. Cells were assigned to 4 treatment groups: control (NT), chronic exposure and transformed (iAs-T), withdrawal
(iAs-Rev-cells were treated for 26 days with iAs, then iAs was removed and cells grown for another 10 days) or retreatment (same as iAs-Rev but
after these 10 days, cells were retreated with iAs for another 10 days). This latter experiment tests for the genes altered immediately by iAs-exposure.
These groups were chosen based on observations to changes in cell morphology. Furthermore, these time points are intended to capture transcription
changes due to long term arsenic exposure and withdrawal.
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digested DNA fragments resolved by agarose gel electro-
phoresis (Figure 3A). NRL an indication of chromatin
compactness was measured according to Nalabothulla et
al, [23]. A single basepair change in NRL, could allow for
a transcription factor-binding site previously occluded by
the nucleosome to become available, resulting in changes
in transcriptional outcomes [23,24]. Measuring the NRL
in these experiments revealed a distinct increase in NRL
of ~4 bp from NT to iAs-T Beas-2B cells (from 191 to
196 bp - compare locations of the blue and red bars
that indicate nucleosomal ladder in Figures 3A - B).
Interestingly, our observed NRL changes correlate
Figure 2 Chronic low dose exposure of sodium arsenite changed cell morphology. A) In HeLa cells B) In BEAS-2B cells after 30 days in culture,
starting to show some elongated characteristics and at 36 days showed elongated, fibroblast-like shape. Phase-contrast microscopy observed
the morphological changes of HeLa and BEAS-2B cells. All images were obtained at a magnification of × 100. C) Confirmation of EMT transition
using western blot analyses of known EMT markers, claudin-3, Vimentin and β-catenin. D - G: Chronic exposure to low dose iAs-exposure alters
cell growth. Proliferation of non-treated and cells treated with inorganic arsenite continuously for several weeks. Growth rate curves were generated
by growing cells and counting them every 2-3 days at 80% confluency. Growth curve of NT and iAs-treated cells D) BEAS 2B and E) HeLa cells. Data
are mean S.E.M. of 3 independent experiments; P < 0.01. Sodium arsenite extends lifespan of F) BEAS-2B and G) HeLa cells. Cumulative population
doubling curves of BEAS-2B cells (left) and HeLa (right) in normal growth medium (blue lines) or cells exposed to 0.5 μM sodium arsenite (red lines).
Viable cells were counted weekly by trypan blue staining using a hemacytometer. Population doublings were calculated by the formula log [(number
of cells harvested)/(number of cells seeded)]/log2. Each graph depicts the averaged results from three longevity assessments.
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with the observed morphological changes in cells seen in
Figure 2. The observed NRL changes are dose dependent
(Figure 3C - D), an increase of ~5 bp is observed in HeLa
cells treated with 0.5 μM iAs, with a further ~4 bp in-
crease in 1 μM iAs-treated cells (166 bp in NT to 171 bp
in 0.5 μM to 174.9 bp in 1 μM cells). Furthermore, re-
moval of Na3AsO3 from 1 μM-transformed cells for
10 days (known as iAs-Rev) resulted in a ~3 bp decrease
in the NRL (174.9 bp to 171.8 bp) (Figure 3C - D).
Our results suggest that iAs-induced cellular transform-
ation results in chromatin with less periodicity and re-
duced average nucleosomal spacing, with the consequence
being heterochromatinization. We further confirmed the
increase in chromatin compaction by showing that chro-
matin from iAs-T cells was more resistant to stringent di-
gest by MNase (Additional file 3: Figure S3). Decreased
nucleosome periodicity and MNase inaccessibility are all
typical of heterochromatin formation and transcriptional
repression [23]. Our data showing increased NRL sup-
ports a role for arsenic in the assembly of repressive chro-
matin [5], although the mechanism is not clear.
Furthermore we show arsenite treatment resulted
in ~30% increase in histone H1 protein levels (data not
shown), supporting our hypothesis of heterochromatiza-
tion, as histone H1 is known to create heterochromatin
and promote longer NRL. Histone H1 and other
Figure 3 Arsenite treatment causes a reduction in nucleosome spacing. A) Nuclei from control and arsenic-transformed BEAS-2B cells were
treated with MNase and the profile of bulk chromatin was analyzed by gel electrophoresis to calculate the nucleosome repeat length (NRL). B) Plot of
nucleosome number versus DNA length for MNase-digested bulk chromatin of BEAS-2B cells ± arsenic. This plot was used to calculate the corresponding
NRL. Data from 3 independent experiments has been pooled and the average ± SD is shown. Blue bars and red bars correspond to nucleosome ladders
from NT and iAs-T cells respectively. C) Similar studies were done in HeLa cells and D) NRL was calculated in NT, iAs-T and iAs-Rev cells.
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chromatin architectural proteins (CAPs), high mobility
group protein-1 (HMGN1) and poly-ADP-ribose polymer-
ase (PARP-1) bind reciprocally to create chromatin struc-
tures that specify transcriptional outcomes [23,25,26].
Therefore, we next tested whether this arsenic-induced
upregulation of histone H1, changes CAP-chromatin asso-
ciation patterns. Consequently we carried out salt frac-
tionation of chromatin (Figure 4A) from HeLa cells (NT,
iAs-T with 0.5 μM and iAs-T with 1 μM Na3AsO3 for
45 days) respectively, with the expectation that different
subsets of CAPs-bound chromatin would be detected in
these three cell conditions. As shown by western blot ana-
lyses, though iAs treatment induced changes in the pro-
tein concentration of these CAPs it does not change the
pattern of their association with specific chromatin frac-
tions. For instance, though H1 concentration increased
globally, its strong association with insoluble 600 mM
NaCl and pellet chromatin fractions did not change. Like-
wise, though globally downregulated with iAs treatment,
HMGN1 was mostly present in the soluble chromatin frac-
tion (Figure 4B). There are likely two processes taking place
with Poly-ADP-ribose polymerase (PARP-1). 1) Arsenite se-
lectively interacts with the zinc finger domains of PARP-1
[27], and releases it from DNA. Our data supports this view
as we see a dose-dependent increase in PARP-1 associated
with the more soluble chromatin fractions. 2) We observe
an increase in cleaved PARP-1, a marker of apoptosis, al-
though an increase in apoptosis was not observed in the
cells. We posit that that some amount of apoptosis is oc-
curring, which was not detected by our bulk DNA frag-
mentation studies. Lastly, we detected a dose-dependent
increase in insoluble chromatin as represented by the in-
crease in the 600 mM and pellet chromatin fractions (Fig-
ure 4C). Overall, our findings of increased repressive H1-,
decreased activating HMGN1- and PARP-1-bound chro-
matin, with a decrease in MNase accessibility, are consist-
ent with increase heterochromatinization of chromatin by
arsenite exposure.
Figure 4 Protein and DNA characterization of chromatin from HeLa cells with/without arsenic treatment. A) Chromatin-fractionation
procedure. B) SDS–polyacrylamide gel analysis (SDS-PAGE) of chromatin architectural proteins (CAPs) and other chromatin proteins in salt
fractions. Equal aliquots of fractions from successive extraction steps in a typical experiment were loaded onto a 4-12% polyacrylamide gel,
which was electrophoresed and westernblotted for the various proteins. C) Ethidium bromide–stained agarose gel showing a typical MNase
ladder of DNA purified from MNase-treated nuclei (MNase); followed by ladders of DNA purified from the nuclear supernatant (Supn); successive
80 mM, 150 mM, and 600 mM extractions; and the remaining pellet, as indicated in (A).
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Profile of arsenic-mediated differentially expressed genes
(DEGs)
After establishing that the observed phenotypic changes
in iAs-T cells correlate with changes in chromatin struc-
ture, and considering that changes in chromatin structural
dynamics typically result in alterations in gene expression,
we sought to determine the genes whose expression is
modulated in iAs-mediated EMT. Such analyses will likely
identify the genes responsive to the long-term exposure to
low dose of iAs (and iAs-transformation) on a genome-
wide scale as well as their functional roles. For this ana-
lysis, RNA from HeLa NT cells and iAs-T HeLa cells
were analyzed using the Affymetrix GeneChip® Human
Transcriptome Array 2.0. First we filtered and retained
differentially expressed genes (DEG) with an FDR < 0.05.
Using SAM analyses, we identified 683 DEGs deregulated
by iAs-T, with 270 under-expressed and 413 over-
expressed (Additional file 4: Table S1). Given the low ra-
tios of differential expression overall, we further narrowed
our gene lists and considered a cut-off ratio of 1.2 fold
as being potential biologically relevant. We first tested
whether previously identified arsenic-altered genes were
also identified in our study. We observed that the top
downregulated genes include ion and anion trans-
porters, as well as several zinc finger-binding proteins
[28] (Additional file 5: Table S2). Additionally, some of
the highly down-regulated genes observed include: Major
Histocompatibility Complex, Class II, DR Alpha (HLA-
DRA) cluster of differentiation 36 (CD36), collagen and
homing cell adhesion molecule (CD44), while one of the
most highly up-regulated genes in our studies is heme-
oxygenase-1 (HMOX1) [29,30].
Functional enrichment analyses of the arsenic-mediated
differentially expressed genes
We performed Protein ANalysis THrough Evolutionary
Relationships (PANTHER) [31] on the DEGs, to identify
significant gene ontology molecular function (GO MF)
and gene ontology biological process (GO BP) terms.
The purpose of this analysis was to find important bio-
logical functions and processes that characterize the impact
of the DEGs identified in this study (Figure 5A & C).
Among the GO BP terms identified by PANTHER, the
most significantly enriched terms are “cellular process regu-
lation”, and “metabolic process regulation” with 76 and 85
genes assigned to these terms respectively. And since heavy
metals disrupt a wide variety of metabolic processes [32]
we decided to analyze this group of genes further.
Metabolic processes are divided into ‘primary’ (required
for cell growth and survival) and ‘secondary’ metabolic
processes (not required in cell survival). Our analyses
showed that arsenite exposure mainly targeted the “pri-
mary metabolic processes”. Proteins within this pathway
are involved in carbohydrate, amino acid, nucleobase, lipid
and protein metabolism (Figure 5B). Like other heavy
metals, arsenic has been hypothesized to outcompete the
binding of nutrient elements to regulatory proteins (recep-
tors, transporters and storage proteins), resulting in
marked aberrations in the metabolism of carbohydrate,
protein/amino acids and lipids [32]. At the protein meta-
bolic level, arsenic-mediated cellular transformation re-
sulted in changes in the expression of genes involved in
ubiquitination, lysosomal degradation, protein modification
and proteolysis [2] and references therein. Consistent with
this, we found several DEGs functioning in proteolysis,
protein folding, protein phosphorylation and protein modi-
fication (Figure 5B), further confirming the role of iAs in
these processes. At the nucleobase metabolic level (a
primary metabolic process), iAs exposure mediates the
expression of proteins involved in DNA repair pro-
cesses, RNA metabolism and purine metabolic processes
(Figure 5B). In addition, changes in the expression pat-
terns of some transcription factors were observed. These
results suggest that not only does arsenic selectively inter-
act with zinc finger containing proteins and prevent their
binding to DNA [33], but also that arsenite-mediated sig-
naling pathways regulate the expression of certain tran-
scription factors (Additional files 4 and 5: Tables S1 – S2
for iAs-mediated target genes and their corresponding
transcription factors). Finally, we also present a visual
summary of the arsenic mediated biological processes
using ‘categoryCompare’ [34] (Figure 5C).
To further identify regulatory mechanisms that poten-
tially underlie the arsenic-modulated transcript levels,
we investigated whether binding sites for specific tran-
scription factors were enriched computationally in the
promoter regions of these iAs-modulated gene sets using
Gene Set Enrichment Analysis (GSEA). These analyses
identified an enrichment for the following transcription
factors: E12 (p < 5.42e-07), FOXO4 (p < 5.94e-05), LEF1
(9.41e-05), Myc-associated protein z (MAZ with p < 0.0016),
Nuclear factor of activated T-cells (NFAT with p < 0.0051),
Forkhead RElated Activator 2 (FREAC2 with p < 0.00016),
ETS2 (p < 0.0071), and GATA4 (p < 0.0051) amongst others
(Additional file 6: Table S3). Since the expression of these
transcription factors were not affected by iAs, we postu-
late that the iAs dependent modulation of chromatin
structure results in differential binding of these transcrip-
tion factors to their respective promoter target sites, with
consequences in specific gene expression patterns. We
hypothesize that this may be the mechanism by which iAs
alters gene expression of key genes associated in cancer
development. Indeed modulation of the expression of all
of these transcription factors - E12 [35]; FREAC2 [36,37];
FOXO4 [38]; LEF1 [39]; NFAT [40]; GATA4 [41]; ETS2
[42] have been implicated in altered gene expression
during EMT. Thus, rather than change the expression of
these factors, iAs may modulate their function by mediating
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Figure 5 Biological processes associated with arsenite-altered DEGs in cells. A) Following PANTHER Pathway analysis, the biological
processes linked to genes are illustrated. Each sector of the pie chart represents the total number of genes expressed for each cellular and
biological function. Genes were filtered for an absolute value log2 ratio ≥1.2 and a significance value of p ≤ 0.05. B) In depth analyses of the
metabolic processes of iAs-target genes. Level 1: Pie chart indicates relative proportions of genes found to be involved in this process. Level
2: Primary metabolic process and genes associated. Level 3a: genes involved in protein metabolic process while Level 3b: Genes involved in
the nucleobase metabolic process. C) categoryCompare [34] showing the biological processes (grouped according to gene ontology terms)
in which the DEGs (upregulated or downregulated) identified in each of the three conditions (iAs-T, iAs-Rev and iAs-rev-ReTreat) compared
to NT. Each node represents a gene ontology (GO) term, and all of the nodes pose KEGG p-value < 0.05 and FDR q-value < 0.05. Color code
is shown in the figure legend. Also indicated are processes that go either up or down in the various conditions. When no up or down is
placed next to the condition, it means that some genes in this biological process that were up or downregulated. Shown also are significant
terms including ‘metabolic processes’ and ‘cell adhesion’ in arsenic treatment (iAs-T and iAs-rev-reTreat), while Mitosis and DNA repair are
among the most significant in iAs-rev cells. Tables used for creating this graph are in Additional file 7: Table S4.
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chromatin structures that disfavor functional binding to
their target sites. However, further studies will be carried
out to determine if this is true.
Gene regulatory pathways modulated by iAs during the
process of transformation
We next set out to identify the gene regulatory pathways
that were activated in HeLa cells chronically exposed to
a low dose of sodium arsenite producing EMT. We
employed the GSEA to identify modulated KEGG (Kyoto
Encyclopedia of Genes and Genomes) pathways in our
microarray data (Additional file 7: Table S4). We did not
observe changes in the gene expression levels of stress re-
sponse genes, such as heat shock proteins in iAs-T cells.
However the expression of some DNA repair proteins
namely Endothelial pas domain 1 (EPAS1), CD36 and O-6-
methylguanine-DNA methyltransferase (MGMT) were
down regulated, while HMOX1 was upregulated. In
addition, the PANTHER analysis revealed several altered
pathways (Additional file 8: Table S5 respectively), includ-
ing the ‘angiogenesis’, ‘Apoptosis’, ‘p53’, ‘Inflammation’, ‘Wnt
signaling” and ‘Integrin signaling’ pathways being highly al-
tered. These results suggest that iAs targets integrins to
promote EMT. For disease associated pathways, there was
an over-representation of cancer pathways and the genes
found in the cancer modules are shown in Additional file
8: Table S5.
DEG patterns after removal of Na3AsO3
In view of the observation that withdrawal of iAs, re-
sulted in a ‘reversion’ both in cell morphology and NRL
towards NT cells, we therefore sought to determine
whether there was a concomitant alteration in gene ex-
pression. Hence, RNA from iAs-Rev cells (as shown in
Figure 1) was analyzed using microarray analysis to pro-
file the gene expression patterns. Comparison analysis of
the DEGs between iAs-Rev and NT cells, found only 39
genes that were not differentially expressed in NT condi-
tions. We theorize that because this set of genes did not
revert to NT levels, that these genes are probably in-
volved in the progression of the defunct gene expression
states seen in iAs-T cells.
Next, we analyzed the changes in gene expression be-
tween iAs-T and iAs-Rev cells. Our results suggest that the
exposure time period and the reversion time period had a
significant number of common genes. Indeed, Venn-
diagram analyses showed 26 DEGs common between these
two cell populations (Figure 6A and Additional file 9:
Figure S4). These data indicate that most genes that re-
spond to iAs exposure and transformation reverted to
their normal levels at 10 days after withdrawal of iAs.
However, the expression of some key genes remain per-
manently altered, possibly resulting in the ability of these
cells to differentiate and become tumorigenic. Further
analysis of the different biological processes affected in
iAs-T and iAs-Rev conditions revealed that the cellular
and metabolic processes are the top-altered biological pro-
cesses. Furthermore, withdrawal of iAs from iAs-T cells
(iAs-Rev) resulted in the reduction of the percentile of
genes within the ‘response to stimulus’ group, indicating
that this process is no longer needed in the absence of the
toxin. On the other hand, we observed an increase in the
percentile of ‘apoptotic’ genes (Figure 6B), also correlating
with the fact that in the absence of iAs, there is a decrease
in the ability of these cells to transform. These results sup-
pose that apoptotic resistance could be a mechanism for
iAs-induced malignant transformation.
Finally, because we were primarily interested in identifying
processes influenced during iAs-induced cellular transform-
ation, we analyzed the DEGs found in the following condi-
tions: NT vs. iAs-T, NT vs. iAs-Rev and iAs-T vs. iAs-Rev.
Overlapping genes represent those genes that were perman-
ently changed in iAs treatment and transformation (Fig-
ure 6C). Only seven genes were common in all three
conditions: microfibrillar associated protein 5 (MFAP5)- as-
sociated with poor cancer prognosis [43-45], O-6-
methylguanine methyl transferase (MGMT) - involved in
the etiology of cancer [46], MIR3188 –important in post-
translational modifications in cancers, cell adhesion mol-
ecule 2 (CADM2) a tumor suppressor [47], Phospholipase
C-like 1 (PLCL1), Opsin 3 (OPN3), and Peroxisomal bio-
genesis factor 11 alpha (PEX11A). The MFAP5 level is de-
creased about 4.8 fold in iAs-T compared to NT cells.
Interestingly, in iAs-Rev, its expression increased compared
to iAs-T. However, its expression levels never returned to
the levels in NT cells (Figure 6D - E). For MGMT, CADM2
and PEX11A, their levels went down in iAs-T cells, and
remained low even in iAs-Rev cells. In the case of PCL1,
compared to NT cells, its expression was downregulated in
transformed cells and interestingly in reversed conditions
the expression of PCL1 went up compared to NT cells. And
lastly, the opposite was true for OPN3 and MIR3188, where
the gene expression levels were up in iAs-T cells, but went
down in iAs-Rev cells. Remarkably, some of these expres-
sion patterns were maintained in the same direction even
when iAs was reintroduced into iAs-Rev cells (Additional
file 10: Figure S5), suggesting a direct effect of iAs on the ex-
pression of these genes. These expression patterns were vali-
dated using qRT-PCR (qunatitative reverse transcription
PCR) analysis for MGMT, OPN3 and PEX11A in HeLa
cells. These changes in gene expression patterns were subse-
quently confirmed in BEAS-2B cells, indicating that these
genes may universally be targets of iAs carcinogenesis
(Figure 6F).
We next determined the biological relevance of these
proteins, by using ‘STRING’ (Search Tool for the Re-
trieval of Interacting Genes/Proteins) [48] to examine
their possible interacting partners. From the STRING
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Figure 6 Analyses of common genes and their biological function between iAs-T and iAs-Rev cells. A) Venn diagram analyses showing the genes
common between the two conditions. B) We used 100% stacked column analysis to compare the changes and biological functions of genes
under arsenic treatment and in reversed conditions. Bar graph representing the percentage of genes and their biological process altered in iAs-T
and after iAs is withdrawn from iAs-T, referred to as iAs-Rev cells. C) Identification of unique and shared genes between iAs-T and genes that did
not revert after arsenic is withdrawn. The Venn diagram indicates the number of unique and common differentially expressed genes at each
treatment condition. D) Heatmap analysis of gene expression changes from microarray data in iAs-T and iAs-Rev cells. The analysis shows relative
fluorescence from green (downregulated) to red (upregulated) of the six genes found common in the experimental conditions. qRT-PCR analyses
to validate the microarray data in E) HeLa cells and F) Beas-2B cells.
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gene/protein network analyses, it is clear that several
molecular markers interacted strongly with the target
genes/markers we studied here. For instance, MFAP5 in-
teracts with several matrix factors, cell adhesion proteins
and is predicted to inhibit NOTCH1 (Additional file 11:
Figure S6A); MGMT interacts with several important DNA
repair proteins, either directly or indirectly (Additional
file 11: Figure S6B); OPN3’s interacting partners are
collagen factors critical in the structural integrity of the
cell (Additional file 11: Figure S6C); Pex11A on the
other hand, interacts with PPARA, NCOA2, CREBBP,
SMARCD3 (Additional file 11: Figure S6D) [12] while
CADM2 interacts with several zinc finger transcription
factors (Additional file 11: Figure S6E). Interestingly,
most of these genes above have cell membrane func-
tions and since dynamic changes of membrane structure
are intrinsic to organelle morphogenesis and homeosta-
sis, their disruption could be lethal. Lastly we used a
systems biology tool, miRUPnet [49] to infer the func-
tional importance of mir3188 and showed that most of
its target genes are critical in several cancer pathways
and its most significant ‘GO term’ is chromatin binding.
Thus each of these proteins and microRNA could serve
as important protein interaction/target hubs that if
deregulated, will have important consequences in the
normal development of a cell. Overall, we show dynamic
changes in gene expression as some genes get reacti-
vated in cells where iAs was introduced after reversal.
In other cases very new genes that were earlier not
activated became altered after reintroduction of iAs
(iAs-rev-reTreat – cells) (Additional file 5: Table S2).
These results imply that low doses of iAs trigger adap-
tive responses that alleviate the adverse effects of arse-
nite cytotoxicity and oxidative stress.
Validation of the microarray data confirms the iAs-
modulated chromatin structural changes mediate altered
gene expression patterns
We used both Western blot analyses as well as qRT-
PCR to confirm changes in gene expression both at the
protein and transcript levels respectively. Selected from
the iAs-modulated networks, Western blot analyses
confirmed the upregulation of HMOX1 and growth dif-
ferentiation factor 1 (GDF1) in iAs-T cells, and down-
regulation of CD36 and claudin3 (CLN3) (Figure 7A
and Additional file 1: Figure S1). Additionally qRT-PCR
expression validated some of the targets shown earlier and
the values did not differ significantly from microarray
values (p > 0.05) (Figure 6D). Furthermore, we show that
these changes in gene expression pattern correlate with
iAs-mediated changes in nucleosome occupancy over the
promoter regions of these genes (Figure 7B). These results
further support our idea that iAs-induced changes
in chromatin structural rearrangements are coupled with
changes to gene expression patterns.
IAs-exposure mediates alternative splicing of specific genes
Organisms use alternative splicing to increase transcrip-
tome diversity necessary to cope with environmental
stress. We therefore asked whether iAs effects specific
alternative splicing isoforms needed for the adaptive be-
havior of cells treated with a low dose of iAs. We used
the GeneChip® Human Transcriptome Array 2.0 (HTA
2.0) for analyzing differential gene expression studies to
analyze differential splicing patterns in NT and iAs-T
cells. Interestingly, iAs was found to induce alternative
splicing events in 104 genes (p < 0.05) (Additional file 12:
Table S6), indicating that iAs does not impact the general
splicing mechanism but is specific for a subset of genes.
Interestingly ~75% of these alternative splicing events
occur in genes whose expression levels were downregu-
lated during iAs-transformation (Figure 8A). We therefore
asked whether the observed splicing patterns were due to
down regulation of the genes rather than splicing. To an-
swer this question, we analyzed splicing patterns of two
downregulated genes - Matrix gla protein 1 (MGP1) and
Neural Cell adhesion molecule 1 (NCAM2) and an upreg-
ulated gene - ATP-binding cassette sub-family G member
2 (ABCG2) [50]. Semi-quantitative RT-PCR was per-
formed on total RNA samples harvested from NT, iAs-T
and iAs-Rev HeLa cells; and NT and iAs-T BEAS-2B cells,
using primers designed to distinguish between the vari-
ants. Results of the changes in specific isoform expression
patterns are shown in Figure 8. In the case of ABCG2, in
iAs-T cells (HeLa as well as BEAS-2B), there was an in-
crease in expression of this gene. Furthermore, exposure
to iAs, resulted in the expression of specific isoforms (Fig-
ure 8B). For the MGP gene, generally there was downreg-
ulation of the expression of this gene transcript
confirming the microarray data. Interestingly, there was
an increase in the expression of isoform 2 in iAs-rev HeLa
cells while the increase in this isoform occurred in iAs-T
BEAS-2B cells. We speculate that these differences might
be due to cell-type specificity or the degree of tumorigen-
esis (bearing in mind that HeLA cells are carcinogenic)
(Figure 8B). However, the results for NCAM2 were even
more dramatic. Two bands were observed in NT cells,
both representing known isoforms. Strikingly, the longest
isoform with all three exons is absent in iAs-T and iAs-
Rev HeLa cells. The next known isoform, isoform 3 having
exons 1 and 3, was again absent in all other conditions ex-
cept in iAs-T-BEAS-2B cells. While these known iso-
forms were observed, bands representing putative novel
isoforms (isoforms 2 and 4) were seen in iAs-T HeLa
cells, and only isoform 4 was seen in iAs-Rev HeLa cells.
In BEAS-2B cells, some level of expression of isoform 4
was seen in NT cells, and the amount of it increased
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significantly in iAs-T BEAS-2B cells. It is possible that these
isoforms are needed for cell-type specificity (difference be-
tween NT BEAS-2B and HeLa) as well as in cellular adap-
tation to arsenic exposure (appearance of isoform 4 in iAs-
T BEAS-2B and HeLa cells). More studies are therefore re-
quired to delineate the relevance of each of these NCAM2
isoforms in iAs-induced carcinogenesis. Taken together,
these results demonstrate that iAs can impact alternative
splicing of a subset of genes, critical in disease pathology.
To date, there have been no studies implicating arsenic in
the regulation of splicing or the splicing machinery and it
will be interesting for future studies to determine how
each of these isoforms potentiate the carcinogenic po-
tential of iAs.
Discussion
iAs is a well-established carcinogen that induces a number
of pathological diseases including several cancers [3-5].
However, the molecular mechanism underlying As3+ in-
duced disease pathology and the downstream genes that
mediate As3+ carcinogenicity are not completely under-
stood. Several studies have been carried out to determine
genes as well as pathways involved in arsenic-induced cellu-
lar adaptation to toxicity and pathogenesis [3]. Adaptation
includes alterations of genes that are needed for cellular
survival in their new environment. Thus the identification
of iAs-induced gene alterations at the transcriptional and
post-transcriptional levels is required to fully understand
As3+ mediated cellular adaption, and to date has been
Figure 7 Immunoblot analysis of iAs-target genes in both HeLa and BEAS-2B cells. A) Shown are representative immunoblots with
expanded views of antibody-decorated bands. Immuno-decoration was carried out with primary antibodies against the respective proteins CD36,
GDF15, HO-1. Besides the individual immunoblots are shown panels, which give a graphical representation of the immuno-decoration levels of
the various proteins (Student’s t-test p < 0.05). B) MNase-treated DNA from cells from all experimental conditions was subjected to quantitaitive
real-time PCR analysis using primers that map to the promoters of the respective genes. Note that changes in nucleosome occupancy correlates
with the gene expression patterns of the various genes in the different experimental conditions. The average results ± SD from two independent
experiments are shown.
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lacking. To fill this gap we have carried out a systematic
and comprehensive study to determine the structural
changes to chromatin and cellular changes elicited by ar-
senic exposure.
First we show that chronic exposure of ‘normal’ hu-
man bronchial epithelial BEAS-2B cells to low doses of
iAs significantly enhanced their ability to grow and
undergo EMT. Likewise, the immortalized carcinoma
HeLa cells underwent further EMT after chronic expos-
ure to low-dose iAs. This is in line with previous studies
showing that HeLa cells can undergo EMT [51-53].
Second, we show that in both cell types, iAs-T cells had
increased nucleosome repeat length, indicative of
heterochromatinization. Correspondingly the levels of
chromatin-bound histone H1 increased with a concomi-
tant decrease in the activating CAP HMGN1. These
changes in chromatin structure correlate with alterations
in gene regulation both with respect to transcription initi-
ation and alternative splicing. Third, the gene expression
profile of iAs-Rev cells showed a remarkable reversal of
many chromatin and gene expression patterns. However,
some key genes that might be oncogenic remain altered in
these reversed conditions. Interestingly, iAs-induced chro-
matin changes facilitate the altered gene expression pat-
terns (Figure 5). Fourth, not only are gene expression
patterns altered but microRNAs expression is altered as
well, suggestive of their function in iAs-induced pathogen-
esis (Additional file 13: Table S7). Some of these miRNAs
regulate the expression of known oncogenes or tumor
suppressor genes, thus acting as onco-miRNAs or tumor-
suppressor miRNAs [54]. Fifth, we show for the first time,
that arsenic exposure results in both changes in gene ex-
pression and in specific transcript isoform expression,
possibly necessary for the adaptive property of these cells
Figure 8 Splicing-sensitive human microarray analysis. A) Distribution of genes that change in gene expression and AS in iAs-T conditions.
Genes whose expression is upregulated and show changes in ASEs (red); genes whose expression is downregulated and show changes in ASEs
(blue). B) Examples of RT-PCR analysis of iAs-mediated alternative splicing events are shown at three genes: ABCG2, MGP, and NCAM2. Primer
locations for each RT-PCR assay are shown by arrows. Each experiment was repeated at least thrice, and data are mean ± SEM with p < 0.05
(student’s t test). The list of iAs-regulated alternative splicing events and the primers used to validate microarray data are available upon request.
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(Figure 8). Together these data indicate that altered gene
expression is a major consequence of chronic As3+
exposure.
Thus our data unveils known and novel pathways
involved in iAs-EMT and suggests that iAs activates sev-
eral signal transduction cascades that lead to changes in
chromatin structure. Bulk chromatin analyses of iAs-T
cells show an increase in NRL indicative of heterochro-
matinization and withdrawal of iAs as in iAs-rev, results
in reduced heterochromatinization. Further supporting
heterochromatinization, is our observation of increase in
histone H1-chromatin binding and upregulation of
DOT1L, the only known H3K79me3 methyltransferase
[55] in iAs-T cells (Figures 3 – 4). These results are in
accordance with previous studies reporting arsenite-
induced increase and decrease in repressive and acti-
vating histone marks respectively [56]. In addition,
recent epidemiological studies confirm that iAs sig-
nificantly increases DNA hypermethylation in a dose-
responsive manner at the promoters of oncogenes
[56,57]. Although our studies do not directly measure
changes in histone PTMs, we did detect changes
nucleosome occupancy at several iAs-target genes.
These studies hint at a potential mechanism by which
iAs-mediated effects alter chromatin structure result-
ing in positive or negative effects on gene regulation.
We also show that specific changes in gene expression
accompany arsenic treatment and withdrawal (Figure 4).
The consequences of repeated and constant arsenite
exposure to cells are manifested by the development of
tolerance, accompanied by changes in chromatin struc-
ture and gene expression patterns. Since humans are fre-
quently on the move, relocation to a newer environment
without the constant insult from arsenite will result in
the establishment of new gene expression patterns.
However, the possibility of developing cancer still exists
based on gene expression patterns that remain altered
even when iAs insult is discontinued (Figure 7C). Indeed
we show in each of the experimental conditions: iAs-T,
iAs-Rev and iAs-rev-reTreat, that cells adapted by chan-
ging the expression of genes both at the transcription
and splicing levels. We observed changes in the expression
of specific microRNAs, (Additional file 13: Table S7) sug-
gesting a role of these microRNAs in the adaptive
responses to arsenic exposure and pathogenesis. It is
possible that the change in gene expression of specific
microRNAs is a mechanism through which iAs exposure
regulates the levels of key proteins. One of these micro-
RNAs modulated by iAs, miR124-1, was recently shown
to target Slug to regulate EMT and metastasis [58]. Over-
expression of miR200b has been implicated in the reversal
and prevention of arsenic-induced malignant transforma-
tions in lung cells [59]. These studies highlight the import-
ance of microRNAs in targeting specific proteins and
driving specific cellular pathways, especially cancer path-
ways [58-62]. Four out of the seven significantly altered
microRNAs target genes important in cancer pathways,
implicating the deregulation of these microRNAs in ar-
senic induced carcinogenesis.
Chromatin structure regulates both transcription initi-
ation and co-transcriptional splicing [63,64]. Therefore it
is likely that in modulating chromatin structure, arsenic
directly affects splicing patterns and/or indirectly by
modulating the expression of splicing factors (Additional
file 12: Table S6). Arsenic has been reported to affect
both positive [65] and negative [66] alternative splicing
events. Organisms use alternative splicing mechanisms
to enhance their ability to cope with stress via transcrip-
tome plasticity [67]. Conceivably, iAs-induced alteration
of gene splicing patterns may underlie the mechanism of
iAs-induced disease pathology. While our exon array
and the validation analyses focused on finding alterna-
tive splicing events that were present in our study, we
also found evidence for considerable heterogeneity. For
example, some of the NCAM2 splice variants differed in
response to the various treatments, suggestive that some
of these NCAM2 isoforms may be potentiating the
metastatic potential of arsenic.
Conclusion
Overall, our comprehensive genome-wide study provides
new insights into markers and mediators of arsenite re-
sponses within a cell. It also identifies known and novel
regulatory pathways involved in the toxicological action
of arsenite. Such detailed and comprehensive studies are
important in dissecting the cause and effect of iAs ex-
posure on signal transduction pathways and its conse-
quences to gene regulatory mechanisms. While iAs is
involved in carcinogenesis, it is also used in the treat-
ment of acute promyelocytic leukemia (APL) [68]. It is
possible that the anti-carcinogenic and carcinogenic ac-
tions of arsenite share a common molecular intersection
that is related to level of arsenite exposure (high dose vs.
low dose), length of exposure (e.g. chronic vs. acute),
and/or exposure to the arsenic species (e.g. arsenite, ar-
senate, MMA, DMA). Thus, it will be important to ask
whether epigenetic changes also mediate arsenic-cancer
therapy. Our studies therefore provide a platform to
begin to define these epigenetic changes.
Methods
BEAS-2B and HeLa cell culture
Cells were obtained from ATCC and cultured maintained
in DMEM supplemented with 10% FBS and 1% penicillin
and streptomycin in a humidified atmosphere with 5%
CO2 at 37°C. Cells were passaged regularly and subcul-
tured to ~80% confluence before conducting the experi-
mental procedures.
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Antibodies
The antibodies cd36, vimentin, claudin3, GDF, β-actin and
HO1 were obtained from Abcam® while PARP1, HMGN1
and H1 were obtained from Activemotif®.
Population doubling number (PDN)
To determine the population doubling number, 4 × 106
cells were plated in 3 cm plates. After 24 hrs the medium
was removed and exchanged for culture medium contain-
ing 0.5 μM or 1 μM of Na3AsO3 (Sigma-Aldrich) and in-
cubated for 5, 10, 15, 21 days. After the treatment period
the cells were washed with PBS and harvested using tryp-
sin/EDTA. The cells were then counted and the popula-
tion doubling numbers were calculated using the equation
the population doubling number = (logN/N0 × 3.31) where
N is the number of cells at the end of the culture period
and the N0 is the number of the cells plated.
Cell transformation by arsenite exposure
BEAS-2B and HeLa cells were continuously exposed to
vehicle control (deionized H2O) or 0.5 μM or 1 μM of
arsenite (Na3AsO3, Sigma-Aldrich), respectively. When
reaching about 80–90% confluence, cells were sub-
cultured and Na3AsO3 was then added to cells after over-
night attachment. These procedures were repeated every 3
or 4 days for 16 weeks. During the exposure period, cell
morphology changes were monitored. Cell malignant
transformation was assessed by changes in cell morph-
ology and EMT marker protein levels.
Cell growth assays
All media were purchased fresh and appropriate
amounts of supplements were added as indicated by the
manufacturer. Cells were incubated at 37°C with humidi-
fied air and 5% CO2. Cells were harvested after each cul-
ture ensuring that the cells had ~95% cell viability.
Harvested cells were centrifuged for five minutes at 200-
x g. Samples were taken each day for counting. Cell via-
bility was determined by trypan blue dye exclusion using
a hemocytometer and calculated as percent viability
times total cells/ml.
Nucleosome-repeat length analyses
Nucleosome-repeat length analysis was done according
to Nalabothulla et al [23].
Salt fractionation of chromatin
Salt fractionation of chromatin was done according to
Teves et al [69].
DNA laddering analysis for apoptosis
DNA fragmentation analysis (DNA ladder) was assessed
by agarose gel electrophoresis according to [22,70] with
a slight modification. iAs-treated or NT HeLa and
BEAS-2B (2 ×106 cells) were collected and centrifuged
at 1200 rpm for 5 min and then re-suspended in a lysis
buffer [50 mM Tris-HCl pH 8.0, 5 mM ethylenediamine
tetraacetic acid (EDTA), 1.2% sodium dodecyl sulfate,
150 mM NaCl, 0.2 mg per ml proteinase K] followed by
incubation at 37°C overnight. Cellular DNA was isolated
by phenol extraction and the DNA samples were carefully
loaded into the wells of a 2.0% agarose gel. Electrophoresis
was carried out in TAE buffer at 50 V for 1 h and the
DNA was visualized by ethidium bromide staining.
RNA extraction and Array hybridization
Total RNA was isolated from cells using a miRNeasy mini
kit (Qiagen) and quality assessment was conducted using
RNA 6000 Nano-labchip (Bioanalyzer, Agilent) and quan-
tified by a Nanodrop spectrophotometer (Thermo). For
transcriptome assay, total cellular RNA (100 ng) was proc-
essed to generate labeled cDNA following the Affymetrix
protocols. The yield of labeled cDNA ranged from 6.27 ug
to 7.57 ug among the 8 samples, of which 4.7 ug cDNA
was applied to Affymetrix Human Transcriptome 2.0ST
arrays (HTA2) for hybridization, one RNA sample per
array. The labeling of RNA samples and hybridization of
HTA2 arrays were performed at the University of Ken-
tucky microarray core facility. The benefit of this array is
to highlight spliced RNA isoforms using both exon and
exon-exon junction probes that can measure excluded or
included exons/regions. HTA 2.0 ST arrays were scanned
using the Affymetrix 3000 7G scanner and the signal in-
tensity of probe hybridization was processed using Com-
mand Console software version 4.1.2.
Gene level analyses
The initial gene expression patterns were done as fol-
lows: Signal intensities of the scanned arrays (.CEL) of
all 8 samples were imported into Partek Genomics Suite
6.6 (Partek, MO) using GCRMA algorithm. Array exon
probes were assembled into genes for statistical analysis
at gene-level to assess significant differential expression
using 1-ANOVA, followed by post-hoc paired compari-
sons among the 4 treatment conditions. More detailed
analyses were done as follows: Analysis at the gene level
first required probe set summarization and normalization.
The raw ‘CEL’ files were processed using the Affymetrix®
Expression Console Software (build 1.3.1.187) with “Gene
Level - Default: RMA-Sketch” normalization to produce
‘CHP’ files for each of the eight samples. The eight CHP
files were then imported into the Affymetrix® Transcrip-
tome Analysis Console (TAC) 2.0 (build 2.0.0.9), using the
“Gene Level Differential Analysis” option. Four conditions
were created within TAC: NT, iAs-T, iAs-Rev, and iAs-
Rev-T according to the conditions in Fig. I. For each con-
dition, the two corresponding replicates were added. Next,
the “Run Analysis” step was performed to determine
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differentially expressed transcript clusters (DETCs). Note
that transcript clusters have been annotated according to
Affymetrix®, and similar to probe sets, do not have a one-
to-one correspondence with protein coding genes. Many
of the transcript clusters correspond to non-coding RNAs
(lincRNAs, snoRNAs, miRNAs) while others have a
many-to-one relationship between transcript clusters and
genes. Comparisons were made to determine DETCs rela-
tive to the NT. An ANOVA p-value cutoff of 0.05 was
used for each comparison, along with a log2 fold change
of ±1.2 (as determined by Tukey’s bi-weight average). The
use of p-value cutoffs alone in microarray gene expression
studies leads to the potential underestimation of variance,
which can result in a large number of false positive differ-
entially expressed genes. Therefore, we additionally incor-
porated a fold change (FC) cutoff to help reduce the false
discovery rate (FDR). We also used volcano plots to dem-
onstrate the relationship between p-values and fold-
change cutoffs. These plots are used in cases where use of
only the p-value or the fold-change alone can lead to re-
sults that are not reproducible, particularly in the case of
genes with low expression levels. Our choice of a log2 FC
cutoff of 1.2 (FC of 2.3 up or down regulated) reduces the
set to a manageable size, resulting in meaningful inter-
pretation with a reduced FDR of 0.05. This sort of
selection criterion is consistent with the results of the
MicroArray Quality Control (MAQC) project [71] which
determined that the use of FC criterion enhances re-
producibility, and P-value criterion balances sensitivity
and specificity.
RNA transcript alternative splicing analysis
Alternatively spliced variants of RNA transcripts were
analyzed using the Partek Genomics suite 6.6 software
(Partek, MO). Briefly, HTA2 array data file (.CEL) of
all 8 samples were imported into Partek GS and the
microarray data was normalized using GCRMA algo-
rithm. Exon probes were summarized into genes and
then, alt-splicing ANOVA-1-way among treatment
groups was run at the gene-level. Gene transcripts
were identified as statistical significant for alternative
splicing at p-value < 0.05.
Categorical annotation
Once differentially regulated genes and exons were de-
termined, a number of different analyses were used for
functional enrichment including: PANTHER [31,72] and
KEGG [73], which finds statistically overrepresented GO
terms within the provided data set; categoryCompare
[34] which provides a cross-platform and cross-sample
comparison of high-throughput data at the annotation
level. Furthermore, STRING [48] was used to assess
protein-protein interactions. Finally, gene lists based on
disease status were analyzed by GSEA [74].
Gene expression and quantitative reverse transcriptase
PCR
Total RNA was isolated using Zymoresearch Quick-RNA™
MiniPrep kit according to the manufacturer’s extraction
protocol (R1054). cDNA was generated from 1μg of total
RNA using the Superscript III First-Strand Synthesis Sys-
tem (Life Technologies). Analysis of mRNA was then
accomplished using primers specific to each of the target
mRNAs. RT-qPCR reactions were performed using
EvaGreen® (Biotium) and Biorad CF96 following the
manufacturer’s instructions and the resulting Ct values
were normalized to GAPDH. Primers for microarray
data validation are available upon request.
Splice variant analysis in the validation series
The validation set was used to measure the predicted
splice variants of 8 genes using specific primers (available
upon request). 1.3 ng of cDNA were analyzed in duplicate
to quantify spliced and unspliced forms by qRT-PCR.
Results were run on an agarose gel stained with GelStar™
Nucleic acid Gel stain (Lonza) and analyzed on a typhoon
for semi-quantitative analyses.
Accession numbers
Data analyzed have been deposited in GEO with accession
numbers GSE60760.
Additional files
Additional file 1: Figure S1. iAs modulates the expression of key EMT
genes in a dose-dependent manner (Figures 1D and 7A). Protein levels
from 3 gels were normalized to the expression of β-actin in both BEAS-2B and
HeLa cells. Data are mean S.E.M. of 3 independent experiments; P < 0.01.
Additional file 2: Figure S2. Low dose of sodium arsenite does not
induce DNA fragmentation in A) BEAS-2B cells and B) HeLa cells. DNA
from control non-exposed cells and arsenic exposed cells were purified
(see Figure 2) and ran on a 3.3% Nusieve agarose gel electrophoresis.
Number of days in culture is shown in figure. NT: non-treated or control
cells. T: iAs treated cells. High concentration of iAs (100 μM) shows the
typical DNA fragmentation pattern (as indicated by arrows).
Additional file 3: Figure S3. Arsenite treatment and transformation
resulted in cells with more compact chromatin. Equal amount of nuclei
was used and digest of chromatin from NT, iAs-T with 0.5 μM and 1μM
iAs respectively cells showed more resistance to micrococcal nuclease
(MNase). Interestingly removal of iAs from 1μM iAs-T, showed an increase
in chromatin accessibility to MNase. Chromatin accessibility is dose-dependent
as more resistance to MNase is seen in chromatin from cells transformed with
0.5 μM iAs compared to 1 μM iAs. Additionally, increase in accessibility is
observed in cells from which iAs is removed (iAs-rev).
Additional file 4: Table S1. Genes upregulated and downregulated by
iAs exposure.
Additional file 5: Table S2. Heatmap showing the differential gene
expression patterns of different solute carrier proteins and zinc-finger
binding proteins modulated in the different experimental conditions.
Additional file 6: Table S3. Transcription factors whose binding sites
were detected at the promoters of iAs-target genes.
Additional file 7: Table S4. Pathways involved by the genes targeted
by iAs. Detailed analyses of the iAs-targeted genes and their association
with cancer (analyzed using GSEA).
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Additional file 8: Table S5. Genes altered by iAs and their association
with various cancer modules.
Additional file 9: Figure S4. Genes common in both iAs-T and iAs-Rev
cells. These analyses show genes that did not revert to NT conditions.
Also shown are the functions of some of these genes.
Additional file 10: Figure S5. Heatmap of the expression pattern of
genes common in iAs-T, iAs-rev and iAs-rev-reTreat cells. Red: indicates
upregulation and green indicates down regulation. From dark green to
light green = low fold change downregulation to more down regulation.
Dark red to light red = degree of upregulation: small to high
upregulation.
Additional file 11: Figure S6. Protein interaction map of altered
iAs-target genes. The bioinformatics STRING database (version 9.1) was
used to generate a protein interaction map with known and predicted
protein associations that include direct physical and indirect functional
protein linkages of microarray identified iAs-target genes at protein level
from Additional file 10: Figure S5). Shown also are the interactors based
on evidence (left side) and confidence level (right side). i) Evidence view:
different line colors represent the types of evidence for the association.
Green: neighborhood; red: gene fusion; blue: co-occurrence; black/grey:
co-expression; pink: experiments; teal: databases; Pea green: textmining;
purple: homology ii) Confidence view: Thicker lines represent stronger
associations.
Additional file 12: Table S6. Genes with iAs-mediated alternatively
spliced events.
Additional file 13: Table S7. MicroRNAs altered during arsenite exposure.
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